|
|
News for Healthier Living
Targeting EGFR Signaling Offers a Promising Path for Airway Mucus Hypersecretion
A new review highlights the epidermal growth factor receptor (EGFR) signaling pathway as a central control point for airway mucus hypersecretion and assesses drugs designed to block it. Excessive mucus production is a shared feature of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and acute respiratory infections, and it is linked to worse lung function and higher mortality. The review synthesizes mechanistic evidence showing how EGFR activation drives goblet cell hyperplasia (GCH) and mucin gene expression, and it evaluates monoclonal antibodies (MABs), tyrosine kinase inhibitors (TKIs), and experimental nanoparticle strategies. Its central message is that EGFR-directed therapy could move mucus management beyond symptomatic relief, although safety and airway selectivity remain critical barriers.
November 2, 2026
November 2 2026November 1 2026October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026
|
|
|
|
|